An interventional study of EXERCISE TRAINING WITH OR WITHOUT MEDICATION in Metabolic Syndrome, Protection Against, Exercise Training and Metformin, sponsored by University of Castilla-La Mancha. Recruiting at 1 site in Spain. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-08-25.
Sponsored by University of Castilla-La Mancha · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 89 studies in Metabolic Syndrome with a site in Spain — 15 open to participants now, 21 under way, none of them phase 3. Metabolic Syndrome · Spain.
Among the 89 studies in Metabolic Syndrome with a site in Spain, this one is the 16th largest by planned enrollment of the 78 interventional ones that give a count, is one of 6 that started in 2022, is one of 66 with no phase, reaches primary completion later than 2 of the 20 other live ones, and was the 48th registered.
2,119 studies on the registry are indexed under Metabolic Syndrome; 350 are open to participants now.
Browse Metabolic Syndrome studies →15 of the 89 studies in Metabolic Syndrome with a site in Spain are open now. Recruiting first, the newest first:
Clinica Universidad de Navarra, Universidad de Navarra · Sites in Spain
Ages 18–75 · Healthy volunteers
IMDEA Food · Sites in Spain
Ages 30–50
Ricardo Mora · Sites in Spain
Ages 18–65 · Healthy volunteers
University of Seville · Sites in Spain
Ages 35–36 · Healthy volunteers
Consorci Sanitari de Terrassa · Sites in Spain
Ages 45–70
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 234 Metabolic Syndrome studies recruiting now, 70 (30%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 81 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
89 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 5 · Phase 3 4 · Phase 4 3
First in 2005; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 160 is above the median of 60 across 1,574 interventional studies indexed under Metabolic Syndrome.
Median enrollment 61 across the 78 interventional studies, 490 across the 11 observational. Of the 53 that completed or were terminated, 3 (6%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 89 have an industry lead sponsor. The 10 most frequent:
University of Castilla-La Mancha is the lead sponsor of 108 studies on the registry; 26 are open to participants now.
University of Castilla-La Mancha has 6 studies filed under Metabolic Syndrome — fewer than ten, so there is no comparison to draw.
5 of the studies in Metabolic Syndrome with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06551285Celia BañulsStudy of the Effect of a Nutritional Supplement on Microbiota, Metabolic Control, Inflammatory Profile, and Quality of Life in Patients With Polycystic Ovary Syndrome. | 2026-12-31 |
| NCT07702695Fundacion Clinic per a la Recerca BiomédicaA Mediterranean Diet-Based Culinary Intervention in Adults With Metabolic Syndrome | 2027-03 |
| NCT06226194Institut de Recerca Biomèdica de LleidaGenetic Susceptibility to Predict Weight Loss After Bariatric Surgery | 2027-03-15 |
| NCT07040748Consorci Sanitari de TerrassaImmersive Virtual Reality Training for Improving Cognition in Adults With Metabolic Syndrome | 2027-04-01 |
| NCT06857929IMDEA Food"Improving Health and Reducing Chronic Disease Risk in Middle-Aged Adults Through Nutrition" | 2027-09-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 89 studies in Metabolic Syndrome with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To analyze the effects of altering the time of ingestion of participants' habitual medication (i.e., metformin, statins, ARAII/IACE) and meals around the time of exercise training (exercise fasted or fed) on the improvement of metabolic syndrome factors (hypertension, insulin sensitivity, dyslipidemia, and obesity). There will be a preliminary study of the effects of training "time-of-day" on the primary study outcomes.
Objective: The purpose is to study in a group of adults with metabolic syndrome and obesity, the effects of altering timing between exercise training, meals, and their habitual medication on the improvement in the factors that compose the metabolic syndrome (i.e., hypertension, insulin resistance, central obesity, and dyslipidemia). The main objective is to find the most productive combination between exercise training and the timing of their habitual pharmacological treatment, and meal ingestion for lowering those factors.
Methods and design: Cross-over randomized double-blinded, pretest-posttest control group experimental design. The project will be developed in a single center with the collaboration of the regional public health system (SECAM). There will be a preliminary study of the effects of training "time-of-day" on three parallel groups of individuals.
Subjects: Will be referred by their primary care physicians to our study unit or recruited by advertisements in local media.
Up to 180 subjects, all of them with metabolic syndrome will be recruited (>25% women).
Measurements:
Specifically, we will study if the cardiovascular and metabolic adaptations to aerobic training that result in amelioration of metabolic syndrome factors are potentiated by correct timming of training, meals, and medicine around exercise training time.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Cardiovascular disease or musculo-skeletal that prevents them from being able to perform intense exercise.
25-32 individuals with metabolic syndrome that will remain sedentary during the 4 months of treatment taking their habitual medication (i.e., blood pressure, glucose, cholesterol, and triglycerides lowering drugs) and meals at the habitual time (CONTROL GROUP).
2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingesting a liquid test meal (500 calls, 50% fat) 30 min before exercise (EXERCISE TRAINING FED).
Drug: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
2 groups of 25-32 individuals with metabolic syndrome that will exercise-train during 16 weeks after ingestion of a placebo meal (0 kcals) 30 min before exercise (EXERCISE TRAINING FAST).
Drug: EXERCISE TRAINING WITH OR WITHOUT MEDICATION
A group will train 30 min after taking their habitual dose of medicine (MEDICATED train) while another group will train after taking a placebo (NON-MEDICATED train) and will receive their medication after training.
Also known as: Exercise timing with respect to medication (metformin, statins, ARAII/ACEI)
Insulin sensitivity assessed using intravenous glucose tolerance test
Curves of insulin-mediated glucose clearance, inhibition of lipolysis, and liver glucose output measured with the use of stable isotope infusion.
Time frame: 12 months
Post-prandial lipemia assessed by an oral fat tolerance test
Rates of appearance and clearance of liver VLDL-TG, Apolipoprotein B, and fatty acids using stable isotopes.
Time frame: 12 months
Blood pressure assessed by ECG-gated automated sphygmomanometer
Determined immediately after treatments and during the following 24-h using ambulatory blood pressure Holter-type monitors.
Time frame: 12 months
Glycemic control assessed by 24-h continuous interstitial glucose monitoring
Determined by a patch glucose sensor paired with a glucose monitor.
Time frame: 36 months
Body composition.
Determined by bioelectrical impedance to calculate body fat mass and fat free mass.
Time frame: 12 months
Body mass index
Determined by body weight (kg) and height (m) to calculate body mass index (kg/m2)
Time frame: 12 months
Maximal oxygen consumption during a graded exercise test to exhaustion, assessed by indirect calorimetry
Calculation of cardiorespitarory fitness
Time frame: 12 months
Resting metabolic rate assessed by indirect calorimetry while lying after an overnight fast
Using indirect calorimetry and a ventilated canopy system
Time frame: 12 months
Maximal rate of fat oxidation assessed by indirect calorimetry during a submaximal exercise test.
Calculated in grams per min during the incremental cycle ergometer test with the use of indirect calorimetry system
Time frame: 12 months
24-hour monitoring of blood concentrations of metformin, statins, and angiotensin blockers assessed using gas chromatography-mass spectrometry.
To study the pharmacokinetics of the habitual medicines used by our subjects during the different experimental conditions
Time frame: 36 months
The activity of intramuscular proteins (enzymes) involved in energetics assessed using western blots.
Measured in skeletal muscle obtained by percutaneous muscle biopsy.
Time frame: 36 months
Plan to share: No — Upon reasonable request
Started Jun 2022 (actual). Primary completion is estimated for May 2024, 23 months after the start.
Of 627 non-industry interventional studies with no phase under Metabolic Syndrome, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 41. This study's planned 23 months is above that.
Counting every sponsor, half of 677 studies reached it within 20 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Castilla-La Mancha →